MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


CORRECT: Advanced Medical Solutions expects full-year revenue growth

ALN

(Correcting dates.)

Alliance News) - Advanced Medical Solutions Group PLC on Wednesday said it expects pretax profit below the previous year, despite delivering strategic progress.

The Cheshire, England-based surgical dressings company said it expects to report full-year revenue between £124 million and £127 million. In 2022, the firm posted revenue of £124.3 million.

The company said it expects adjusted pretax profit between £25 million and £27 million, compared with adjusted pretax profit of GBP 28.5 million in the year prior.

It noted that it has completed a number of strategic marketing initiatives and product launches in 2023. Advanced Medical said its US LiquiBand product is expected to achieve record revenue in 2024.

The company said the full-market launch of its LiquiBandFix8/LiquiFix product is expected in the first quarter of 2024.

Chief Executive Chris Meredith said: ‘I am delighted with the strategic progress we have made across the group in 2023, creating significant new opportunities for AMS. The completion of the new US LiquiBand route to market strategy, the US Connexicon acquisition and the roll-out of LiquiBand XL will support the delivery of record US LiquiBand revenues in 2024 and sets us up

strongly to deliver our target of doubling our market share over the next five years.

‘With the US launch of LiquiFixTM progressing well and continued growth being generated from more established brands such as RESORBA and ActivHeal, we are confident that the Group will generate strong and sustainable growth in 2024 and in the long term.’

Advanced Medical shares rose 4.2% to 211.42 each on Wednesday morning in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.